Chitosan as an adjuvant-like substrate for dendritic cell culture to enhance antitumor effects

Biomaterials

Volumn 35, Issue 31, 2014, Pages 8867-8875

  Lin, Yong Chong ^a   Lou, Pei Jen ^b   Young, Tai Horng ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chitosan; Dendritic cell; Tumor; Vaccine

Indexed keywords

BODY FLUIDS; CELLS; TISSUE CULTURE; TUMORS; VACCINES;

ANTITUMOR EFFECT; CANCER IMMUNOTHERAPY; DENDRITIC CELLS; DENDRITIC CELLS (DCS); LIPOPOLYSACCHARIDES; REDUCTION ACTIVITY; TISSUE-CULTURE POLYSTYRENES; TUMOR PROTECTION;

CHITOSAN;

CD14 ANTIGEN; CHITOSAN; GLYCOPROTEIN P 15095; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; BIOMATERIAL; CANCER VACCINE; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CELL AGGREGATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOCOMPATIBLE MATERIALS; CANCER VACCINES; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; CHITOSAN; DENDRITIC CELLS; HUMANS; MICE; MICE, INBRED C57BL; MONOCYTES; NEOPLASMS;

EID: 84905466499     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.07.014     Document Type: Article

References (47)

1. Boczkowski D., Nair S.K., Nam J.H., Lyerly H.K., Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000, 60:1028-1034.
2. Palucka A.K., Ueno H., Connolly J., Kerneis-Norvell F., Blanck J.P., Johnston D.A., et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 2006, 29:545-557.
3. Okada H. Brain tumor immunotherapy with type-1 polarizing strategies. Ann N Y Acad Sci 2009, 1174:18-23.
4. Dannull J., Haley N.R., Archer G., Nair S., Boczkowski D., Harper M., et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J Clin Invest 2013, 123:3135-3145.
5. Dannull J., Lesher D.T., Holzknecht R., Qi W., Hanna G., Seigler H., et al. Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Blood 2007, 110:4341-4350.
6. Chiang C.L., Kandalaft L.E., Tanyi J., Hagemann A.R., Motz G.T., Svoronos N., et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013, 19:4801-4815.
7. Underhill D.M., Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002, 14:103-110.
8. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999, 5:1249-1255.
9. Forster R., Schubel A., Breitfeld D., Kremmer E., Renner-Muller I., Wolf E., et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999, 99:23-33.
10. Steinman R.M. Some interfaces of dendritic cell biology. APMIS 2003, 111:675-697.
11. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
12. Babensee J.E., Paranjpe A. Differential levels of dendritic cell maturation on different biomaterials used in combination products. J Biomed Mater Res A 2005, 74A:503-510.
13. Seferian P.G., Martinez M.L. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine 2000, 19:661-668.
14. Luzardo-Alvarez A., Blarer N., Peter K., Romero J.F., Reymond C., Corradin G., et al. Biodegradable microspheres alone do not stimulate murine macrophages in vitro, but prolong antigen presentation by macrophages in vitro and stimulate a solid immune response in mice. J Control Release 2005, 109:62-76.
15. Nagamoto T., Hattori Y., Takayama K., Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res 2004, 21:671-674.
16. Porporatto C., Bianco I.D., Correa S.G. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol 2005, 78:62-69.
17. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992, 176:1693-1702.
18. Cheng N.C., Wang S., Young T.H. The influence of spheroid formation of human adipose-derived stem cells on chitosan films on sternness and differentiation capabilities. Biomaterials 2012, 33:1748-1758.
19. Chen Y.H., Wang I.J., Young T.H. Formation of keratocyte spheroids on chitosan-coated surface can maintain keratocyte phenotypes. Tissue Eng Part A 2009, 15:2001-2013.
20. Lin S.J., Jee S.H., Hsaio W.C., Lee S.J., Young T.H. Formation of melanocyte spheroids on the chitosan-coated surface. Biomaterials 2005, 26:1413-1422.
21. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999, 223:77-92.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
23. Schnurr M., Galambos P., Scholz C., Then F., Dauer M., Endres S., et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001, 61:6445-6450.
24. Sallusto F., Lanzavecchia A. Efficient presentation of soluble-antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony-stimulating factor plus interleukin-4 and down-regulated by tumor-necrosis-factor-alpha. J Exp Med 1994, 179:1109-1118.
25. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007, 25:2085-2094.
26. Steele J.G., Johnson G., Griesser H.J., Underwood P.A. Mechanism of initial attachment of corneal epithelial cells to polymeric surfaces. Biomaterials 1997, 18:1541-1551.
27. Steele J.G., Dalton B.A., Johnson G., Underwood P.A. Polystyrene chemistry affects vitronectin activity: an explanation for cell attachment to tissue culture polystyrene but not to unmodified polystyrene. J Biomed Mater Res 1993, 27:927-940.
28. Kleinsoyer C., Hemmendinger S., Cazenave J.P. Culture of human vascular endothelial-cells on a positively charged polystyrene surface, primaria - comparison with fibronectin-coated tissue-culture grade polystyrene. Biomaterials 1989, 10:85-90.
29. Huang G.S., Dai L.G., Yen B.L., Hsu S.H. Spheroid formation of mesenchymal stem cells on chitosan and chitosan-hyaluronan membranes. Biomaterials 2011, 32:6929-6945.
30. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2:52-58.
31. Baek S., Kim C.S., Kim S.B., Kim Y.M., Kwon S.W., Kim Y., et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. J Transl Med 2011, 9:178.
32. Minarik I., Horvath R., Podrazil M., Hromadkova H., Dusek P., Jarolim L., et al. Phase I/II of clinical study of prostate cancer immunotherapy using dendritic cell vaccination strategy - first results. Eur Urol 2010, 9:629.
33. Kavanagh B., Ko A., Venook A., Margolin K., Zeh H., Lotze M., et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 2007, 30:762-772.
34. Bivas-Benita M., van Meijgaarden K.E., Franken K., Junginger H.E., Borchard G., Ottenhoff T.H.M., et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 2004, 22:1609-1615.
35. Wischke C., Borchert H.-H., Zimmermann J., Siebenbrodt I., Lorenzen D.R. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release 2006, 114:359-368.
36. Villiers C., Chevallet M., Diemer H., Couderc R., Freitas H., Van Dorsselaer A., et al. From secretome analysis to immunology chitosan induces major alterations in the activation of dendritic cells via a TLR4-dependent mechanism. Mol Cell Proteomics 2009, 8:1252-1264.
37. Turnis M.E., Rooney C.M. Enhancement of dendritic cells as vaccines for cancer. Immunotherapy 2010, 2:847-862.
38. Okada N., Iiyama S., Okada Y., Mizuguchi H., Hayakawa T., Nakagawa S., et al. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Ther 2005, 12:72-83.
39. Heffernan M.J., Zaharoff D.A., Fallon J.K., Schlom J., Greiner J.W. In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials 2011, 32:926-932.
40. Saika T., Satoh T., Kusaka N., Ebara S., Mouraviev V.B., Timme T.L., et al. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther 2004, 11:317-324.
41. Yang T.L., Young T.H. The specificity of chitosan in promoting branching morphogenesis of progenitor salivary tissue. Biochem Biophys Res Commun 2009, 381:466-470.
42. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., McKenna E.A., Yanik G.A., Levine J.E., et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001, 61:8513-8519.
43. Maier T., Tun-Kyi A., Tassis A., Jungius K.P., Burg G., Dummer R., et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 2003, 102:2338-2344.
44. Jiang X.B., Lu X.L., Hu P., Liu R.E. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine 2009, 27:6210-6216.
45. Kim C.H., Hong M.J., Park S.D., Kim C.K., Park M.Y., Sohn H.J., et al. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol Immunother 2006, 55:1309-1319.
46. Miyazaki J., Tsuzuki Y., Matsuzaki K., Hokari R., Okada Y., Kawaguchi A., et al. Combination therapy with tumor-lysate pulsed dendritic cells and antiangiogenic drug TNP-470 for mouse pancreatic cancer. Int J Cancer 2005, 117:499-505.
47. Kao J.Y., Zhang M., Chen C.M., Chen J.J. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol Lett 2005, 101:154-159.